Comparing Bluejay Diagnostics (NASDAQ:BJDX) and Fresenius SE & Co. KGaA (OTCMKTS:FSNUY)
Comparing Bluejay Diagnostics (NASDAQ:BJDX) and Fresenius SE & Co. KGaA (OTCMKTS:FSNUY)
Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) and Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
BlueJay Diagnostics(纳斯达克代码：BJDX-GET Rating)和Fresenius SE&Co.KGaA(场外交易市场代码：FSNUY-GET Rating)都是医疗公司，但哪项业务更优越？我们将根据这两家公司的分析师建议、估值、风险、机构所有权、股息、盈利能力和收益的强弱对它们进行比较。
Earnings & Valuation
收益与估值
This table compares Bluejay Diagnostics and Fresenius SE & Co. KGaA's revenue, earnings per share and valuation.
下表比较了Bluejay Diagnostics和Fresenius SE&Co.KGaA的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bluejay Diagnostics | N/A | N/A | -$3.49 million | ($0.44) | -1.61 |
| Fresenius SE & Co. KGaA | $44.39 billion | 0.32 | $2.15 billion | $0.82 | 7.73 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| BlueJay诊断 | 不适用 | 不适用 | -349万元 | ($0.44) | -1.61 |
| 费森尤斯SE&Co.KGaA | 443.9亿美元 | 0.32 | 21.5亿美元 | $0.82 | 7.73 |
Fresenius SE & Co. KGaA has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Fresenius SE & Co. KGaA, indicating that it is currently the more affordable of the two stocks.
费森尤斯SE&Co.KGaA的收入和收益高于Bluejay Diagnostics。BlueJay Diagnostics的市盈率低于Fresenius SE&Co.KGaA，这表明它目前是两只股票中更负担得起的一只。
Insider & Institutional Ownership
内部人与机构所有权
Analyst Ratings
分析师评级
This is a breakdown of current ratings and price targets for Bluejay Diagnostics and Fresenius SE & Co. KGaA, as reported by MarketBeat.com.
据MarketBeat.com报道，这是Bluejay Diagnostics和Fresenius SE&Co.KGaA目前的评级和目标价细分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bluejay Diagnostics | 0 | 0 | 1 | 0 | 3.00 |
| Fresenius SE & Co. KGaA | 0 | 5 | 4 | 0 | 2.44 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| BlueJay诊断 | 0 | 0 | 1 | 0 | 3.00 |
| 费森尤斯SE&Co.KGaA | 0 | 5 | 4 | 0 | 2.44 |
Bluejay Diagnostics presently has a consensus target price of $10.00, indicating a potential upside of 1,308.45%. Fresenius SE & Co. KGaA has a consensus target price of $39.34, indicating a potential upside of 520.55%. Given Bluejay Diagnostics' stronger consensus rating and higher probable upside, equities analysts plainly believe Bluejay Diagnostics is more favorable than Fresenius SE & Co. KGaA.
BlueJay Diagnostics目前的共识目标价为10.00美元，表明潜在上行空间为1,308.45%。Fresenius SE&Co.KGaA的一致目标价为39.34美元，显示潜在上行520.55%。鉴于Bluejay Diagnostics的普遍评级更高，上行可能性也更高，股票分析师显然认为Bluejay Diagnostics比Fresenius SE&Co.KGaA更有利。
Profitability
盈利能力
This table compares Bluejay Diagnostics and Fresenius SE & Co. KGaA's net margins, return on equity and return on assets.
下表比较了Bluejay Diagnostics和Fresenius SE&Co.KGaA的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Bluejay Diagnostics | N/A | -47.07% | -43.59% |
| Fresenius SE & Co. KGaA | 4.17% | 5.58% | 2.32% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| BlueJay诊断 | 不适用 | -47.07% | -43.59% |
| 费森尤斯SE&Co.KGaA | 4.17% | 5.58% | 2.32% |
Summary
摘要
Fresenius SE & Co. KGaA beats Bluejay Diagnostics on 8 of the 12 factors compared between the two stocks.
费森尤斯SE&Co.KGaA在比较两只股票的12个因素中有8个超过了Bluejay Diagnostics。
About Bluejay Diagnostics
关于Bluejay诊断公司
(Get Rating)
(获取评级)
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
BlueJay诊断公司是一家诊断公司，在美国开发和销售用于分诊、诊断和监测疾病进展的患者产品。它正在开发一个技术平台，包括使用非接触式离心力协调血液处理、生物标记物分离和免疫分析准备的SYMPHONY荧光免疫分析仪；以及包括试剂和组件的SYMPHONY卡片库。该公司还提供AlLEREYE诊断测试，这是一种用于诊断过敏性结膜炎的POC设备。此外，它还开发用于检测其他疾病的生物标记物，例如用于心肌损伤的hsTnT/I和用于心力衰竭的NT-proBNP。它与东丽工业公司签订了制造和分销蛋白质检测芯片的许可和供应协议。BlueJay Diagnostics，Inc.成立于2015年，总部位于马萨诸塞州阿克顿。
About Fresenius SE & Co. KGaA
关于Fresenius SE&Co.KGaA
(Get Rating)
(获取评级)
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Fresenius SE&Co.KGaA是一家医疗保健公司，为透析、医院和门诊医疗提供产品和服务。它通过四个部门运作：费森尤斯医疗保健、费森尤斯·卡比、费森尤斯·赫利奥斯和费森尤斯·瓦米德。费森尤斯医疗保健部门为慢性肾功能衰竭患者提供产品和服务。这一细分市场提供透析器、血液透析机和相关一次性产品，以及与透析相关的服务。Fresenius Kabi部门从事治疗和护理患病患者的治疗和护理。这一领域提供四种药物，包括用于肿瘤、麻醉剂、止痛剂、抗感染和重症护理的静脉给药的仿制药；肠外和肠内营养产品；用于输液治疗的输液和血容量替代品；生物仿制药，一种治疗自身免疫和肿瘤疾病的生物药物；用于管理四种非专利药物、输液疗法和临床营养产品的医疗器械和处置；以及用于采集血液成分和身体疗法的输血产品。费森尤斯·赫利奥斯分部在德国经营着90家医院、大约130家门诊诊所和6个预防中心；在西班牙经营着49家医院、88家门诊诊所和大约300个风险预防中心。这一部分还通过33个诊所和另外39个地点，在3大洲10个国家提供不孕症治疗服务。费森尤斯·瓦米德部门管理项目，并为医院和其他卫生保健设施提供服务。这一部分提供项目开发、规划和交钥匙建设服务，以及维护和技术管理, 和运营管理服务。该公司前身为Fresenius SE，并于2011年1月更名为Fresenius SE&Co.KGaA。Fresenius SE&Co.KGaA成立于1912年，总部设在德国巴德洪堡Vor der HöHe。
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
接收Bluejay诊断日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收Bluejay Diagnostics和相关公司的最新新闻和分析师评级的每日摘要。